BIOMAT Database Logo BIOMAT Database Logo

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. 2013

Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Laboratoire de Virologie, AP-HP Groupe Hospitalier Bichat-Claude Bernard, HUPNVS, Univ Paris Diderot, PRES Sorbonne Paris Cité, Paris, France. lucile.larrouy@bch.aphp.fr

OBJECTIVE This study investigated the impact on virological outcome of the gag cleavage sites and the protease-coding region mutations in protease inhibitor-naive and protease inhibitor-experienced patients infected with HIV-2 receiving lopinavir (LPV) containing regimen. METHODS Baseline gag and protease-coding region were sequenced in 46 HIV-2 group A-infected patients receiving lopinavir. Virological response was defined as plasma viral load less than 100 copies/ml at month 3. Associations between virological response and frequencies of mutations in gag [matrix/capsid (CA), CA/p2, p2/nucleocapsid (NC), NC/p1, p1/p6] and gag-pol (NC/p6) cleavage site and protease-coding region, with respect to the HIV-2ROD strain, were tested using Fisher's exact test. RESULTS Virological response occurred in 14 of 17 (82%) protease inhibitor-naive and 17 of 29 (59%) protease inhibitor-experienced patients. Virological failure was associated with higher baseline viral load (median: 6765 versus 1098 copies/ml, P = 0.02). More protease-coding region mutations were observed in protease inhibitor-experienced compared with protease inhibitor-naive patients (median: 8 versus 5, P = 0.003). In protease inhibitor-naive patients, T435A (NC/p6), V447M (p1/p6), and Y14H (protease-coding region) were associated with virological failure (P = 0.011, P = 0.033, P = 0.022, respectively). T435A and V447M were associated with Y14H (P = 0.018, P = 0.039, respectively). In protease inhibitor-experienced patients, D427E (NC/p1) was associated with virological response (P = 0.014). A430V (NC/p1) and I82F (protease-coding region) were associated with virological failure (P = 0.046, P = 0.050, respectively). Mutations at position 430 were associated with a higher number of mutations in protease-coding region (median: 10 versus 7, P = 0.008). CONCLUSIONS We have demonstrated, for the first time, an association between gag, gag-pol cleavage site and protease-coding region mutations, with distinct profiles between protease inhibitor-naive and protease inhibitor-experienced patients. These mutations might impact the virological outcome of HIV-2-infected patients receiving LPV-containing regimen.

UI MeSH Term Description Entries
D008297 Male Males
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015498 HIV-2 An HIV species related to HIV-1 but carrying different antigenic components and with differing nucleic acid composition. It shares serologic reactivity and sequence homology with the simian Lentivirus SIMIAN IMMUNODEFICIENCY VIRUS and infects only T4-lymphocytes expressing the CD4 phenotypic marker. HTLV-IV,Human T-Lymphotropic Virus Type IV,Human immunodeficiency virus 2,LAV-2,HIV-II,Human Immunodeficiency Virus Type 2,Human T Lymphotropic Virus Type IV,Immunodeficiency Virus Type 2, Human,SBL-6669
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016333 HIV Protease Enzyme of the human immunodeficiency virus that is required for post-translational cleavage of gag and gag-pol precursor polyproteins into functional products needed for viral assembly. HIV protease is an aspartic protease encoded by the amino terminus of the pol gene. HIV Proteinase,HTLV-III Protease,p16 pol gene product, HIV,p16 protease, HIV,HIV p16 protease,HTLV III Protease,Protease, HIV,Protease, HTLV-III

Related Publications

Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients.
July 2010, Antimicrobial agents and chemotherapy,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Lopinavir plasma concentrations and virological outcome with lopinavir-ritonavir monotherapy in HIV-1-infected patients.
August 2013, Antimicrobial agents and chemotherapy,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.
March 2008, AIDS (London, England),
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
July 2008, Clinical pharmacology and therapeutics,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
January 2004, HIV clinical trials,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
April 2011, Antimicrobial agents and chemotherapy,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
January 2011, PloS one,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen.
January 2002, AIDS (London, England),
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
June 2012, The New England journal of medicine,
Lucile Larrouy, and Alexandre Vivot, and Charlotte Charpentier, and Antoine Bénard, and Benoit Visseaux, and Florence Damond, and Sophie Matheron, and Geneviève Chene, and Françoise Brun-Vezinet, and Diane Descamps, and
The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
August 2004, Antiviral therapy,
Copied contents to your clipboard!